Patent SG-11201901715U-A (SG)
Title: Adenovirus armed with bispecific t cell engager (bite)
Inventor: CHAMPION BRIAN
IPC: C12N15/861
Filed: 2017-08-29
Abstract: 12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111114110111010101111101110100111011110111111411011111011 OEN Organization International Bureau (10) International Publication Number International Publication Date .....0\"\" WO 2018/041838 Al 08 March 2018 (08.03.2018) WI P0 I P C T — (51) (21) (22) (25) Filing Language: (26) (30) (71) International Patent Classification: (72) Inventors: CHAMPION, Brian, Robert; PsiOxus Ther- A61K 39/395 (2006.01) C07K 16/30 (2006.01) apeutics Ltd, PsiOxus House, 4-10 The Quadrant, Barton A61K 35/761 (2015.01) C07K 16/40 (2006.01) Lane, Abingdon, Oxfordshire OX14 3YS (GB). BROWN, CO7K 16/28 (2006.01) Cl 2N 15/861 (2006.01) Alice, Claire, Noel; PsiOxus Therapeutics Ltd, PsiOxus House, 4-10 The Quadrant, Barton Lane, Abingdon, Ox- International Application Number: PCT/EP2017/071674 fordshire OX14 3YS (GB). FREEDMAN, Joshua, David; 83 Manor Road, Chigwell IG7 5PH (GB). FISHER, Kerry, International Filing Date: David; 11 Cassington Road Eynsham, Witney OX29 4LH 29 August 2017 (29.08.2017) (GB). SEYMOUR, Leonard, William; 5 Workhouse Yard Chapel Hill, Wootton by Woodstock OX20 1YD (GB). English Publication Language: English (74) Agent: STERLING IP LTD; Orion House Bessemer Road, Welwyn Garden City, United Kingdom AL7 1HH Priority Data: (GB). 1614607.8 29 August 2016 (29.08.2016) GB (81) Designated States (unless otherwise indicated, for every 1700663.6 13 January 2017 (13.01.2017) GB kind of national protection available): AE, AG, AL, AM, 1706219.1 19 April 2017 (19.04.2017) GB AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 1713765.4 28 August 2017 (28.08.2017) GB CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, Applicant: PSIOXUS THERAPEUTICS LIMITED DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, [GB/GB]; PsiOxus House, 4-10 The Quadrant, Abingdon, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, Oxfordshire OX14 3YS (GB). KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = = Title: ADENOVIRUS ARMED WITH Figure 31 z.- 9, 40 >. With T-cells added .5 R 2 ° 0 5 5, 0 0 -20 60 e 40 Z' - a — 2 No T- cells added g -20 : A modified adenovirus, in particular least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided a composition, such as a pharmaceutical formulation comprising the virus, as in the treatment of cancer. The disclosure also extends to processes for preparing the virus. (54) BISPECIFIC T CELL ENGAGER (BITE) -.I- Uninfected -4-- EnAd -- EnAd-CMV-ControlBiTE -II- EnAd-CMV-EpCAMBiTE . -N- EnAd-SA-ConfrolBiTE -is- EnAd-SA-EpCAMBITE = = — _ — = = = _ = — _ Enadenotucirev (EnAd), armed with a bispecific T cell engager (BiTE) comprising -0- Uninfected -41- IT: nAd -or- Erl - Clibi-ConfmnITE -iv- EnAd- CLIV--rpCA E.' IT -IF EnAd- Z..;A- Cr • , t rk.,1' 1 11 - 2 ill- EnAd-SA-EpCI,LrlfrE = = = _ = = _ GC M GO 1-1 I I - (57) 0 ----. at *t are 1-1 © such eqi use of the virus and virus formulations for treatment, O [Continued on next page] WO 2018/041838 Al MIDEDIMOMOIDEIREEMOMIUMMINIMInin OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))